Candida glabrata is currently ranked as the second most frequently isolated aetiological agent of human fungal infections, next only to Candida albicans. In comparison with C. albicans, C. glabrata shows lower susceptibility to azoles, the most common agents used in treatment of fungal infections. Interestingly, the mechanisms of resistance to azole agents in C. albicans have been much better investigated than those in C. glabrata. The aim of the presented study was to determine the mechanisms of resistance to azoles in 81 C. glabrata clinical isolates from three different hospitals in Poland. The investigation was carried out with a Sensititre Yeast One test and revealed that 18 strains were resistant to fluconazole, and 15 were cross-resistant to all other azoles tested (voriconazole, posaconazole and itraconazole). One isolate resistant to fluconazole was cross-resistant to voriconazole, and resistance to voriconazole only was observed in six other isolates. All strains were found to be susceptible to echinocandins and amphotericin B, and five were classified as resistant to 5-fluorocytosine. The sequence of the ERG11 gene encoding lanosterol 14-a demethylase (the molecular target of azoles) of 41 isolates, including all strains resistant to fluconazole and three resistant only to voriconazole, was determined, and no amino acid substitutions were found. Real-time PCR studies revealed that 13 of 15 azole-resistant strains showed upregulation of the CDR1 gene encoding the efflux pump. No upregulation of expression of the CDR2 or ERG11 gene was observed.
INTRODUCTION
The genus Candida comprises over 150 heterogeneous species (Lass-Flörl, 2009 ), at least 17 of which are known to be aetiological agents of human and animal infections (Silva et al., 2012) . The incidence of fungal infections caused by Candida spp. has increased dramatically during the last three decades, due mainly to the rise in number of immunocompromised patients (Arendrup, 2010; . Currently, candidiasis represents the fourth leading cause of nosocomial infections (8-10 %), and mortality due to systemic candidiasis remains high, ranging from 15 to 35 % depending on the infecting Candida sp. (Pfaller & Diekema, 2007) . Moreover, the annual treatment costs exceed US$10 billion in the USA alone (Jabra-Rizk, 2006) . In most cases, Candida infections are derived from the individual's own endogenous reservoir when the host presents certain risk factors such as immunosuppressive and cytotoxic therapies, treatment with broad-spectrum antibacterial antibiotics, AIDS, diabetes and drug abuse (Pfaller & Diekema, 2007) . Candida albicans is still classified as the most common fungal pathogen in humans, although recently a shift towards systemic infections by non-albicans Candida spp. has been reported (Papon et al., 2013) . In a tertiary paediatric hospital in Poland, the prevalence of non-albicans species increased from 12.5 % in 2000 to 70 % in 2010 (Dzierża-nowska-Fangrat et al., 2014 . It has been observed worldwide that one of most frequently isolated non-albicans species is Candida glabrata (Papon et al., 2013; Rodrigues et al., 2014) . This species lacks a number of the virulence factors allied to other Candida spp. pathogenicity, such as hyphal growth, the ability to secrete proteases and efficient adhesion to the surface of host tissue (Kaur et al., 2005; Rodrigues et al., 2014) . It is believed that the increase in the number of C. glabrata infections is mainly a consequence of its intrinsically low susceptibility to azoles, agents used commonly for the treatment and prevention of fungal infections (Tscherner et al., 2011) . Similar to some other species in the genus Candida (especially C. albicans), C. glabrata belongs to the natural microbiota of the oral cavity, gastrointestinal and vaginal tracts of humans (Rodrigues et al., 2014) . Elimination of other yeast species from the host organism through azole abuse leads to selection and overgrowth of resistant strains of C. glabrata, causing different clinical manifestations, starting from minor infections of mucosal membranes to life-threatening invasive infections (Chavanet et al., 1994) .
The most important factors affecting the low level of susceptibility of C. glabrata isolates to azoles are similar to those found in C. albicans and include overexpression of genes encoding the most important ABC drug transporters, namely Cdr1p and Pdh1p (known also as Cdr2p) (Rodrigues et al., 2014; Sanglard et al., 1999 Sanglard et al., , 2001 Sanguinetti et al., 2005) , as well as upregulation of genes involved in the biosynthesis of ergosterol, especially ERG11 (Marichal et al., 1997; Rodrigues et al., 2014) . Interestingly, in contrast to C. albicans, most of the investigations carried out in different regions of the world have revealed that point mutations within the ERG11 gene of azole-resistant C. glabrata isolates are rarely identified or are not present at all (Berila & Subik 2010; Berila et al., 2009; Sanguinetti et al., 2005) . There also exist many other possible, not fully recognized mechanisms affecting C. glabrata resistance to azoles, such as mitochondrial dysfunction (Ferrari et al., 2011) and calcium signalling (Kaur et al., 2004) . However, they do not seem to be as important as overexpression of drug efflux proteins or enzymes involved in ergosterol synthesis (Rodrigues et al., 2014) .
The aim of the presented study was to analyse the mechanisms of resistance to azole antifungal agents in 81 C. glabrata clinical isolates from three hospitals in Poland. To the best of our knowledge, this is one of the largest populations studied so far.
METHODS
Strains and susceptibility testing. A total of 81 C. glabrata were isolated from a variety of clinical specimens: urine, faeces, blood, fluid from the peritoneal cavity, stoma, bronchopulmonary lavage fluid, and swabs of the mouth, throat and anus from patients at three Polish hospitals: the Children's Memorial Health Institute in Warsaw (n517 isolates, 21 %, collected in 2011 and 2012), the Medical University of Gdansk (n554 isolates, 66.7 %, collected in 2011 and 2012) and the Pomeranian Medical University in Szczecin (n510 isolates, 12.3 %, collected in 2008) . In the Medical University of Gdansk, superficial infections are treated with azoles, and invasive candidosis with azoles and echinocandins. In the period of collection of the strains from Warsaw and Szczecin, only azoles were used for eradication of infections.
Species identification was carried out using three different methods: growth on Chromagar Candida Lab-agar plates (Biocorp), a Candida API test (bioMérieux) and species-specific PCR. All tested strains were cultured on a chromogenic medium and plates were incubated at 37 uC for 24-8 h. C. glabrata isolates were determined by growth as violet colonies. The Candida API test allows identification based on the sugar assimilation patterns, as this species is known to ferment only glucose and trehalose. Molecular identification was carried out according to the method developed by Olchawa et al. (2013) . The species-specific PCR products (423 bp) were detected on 1.5 % agarose gel with the addition of ethidium bromide.
Susceptibility to antifungal agents was determined using the commercially available Sensititre Yeast One test (TREK Diagnostic Systems) . This test enables analysis of the antifungal activity of the nine most common antimycotics, over the range of concentrations indicated (mg ml 21 ): micafungin, 0. 008-8; caspofungin, 0.008-8; 5-fluorocytosine, 0.06-64; posaconazole, 0.008-8; voriconazole, 0.008-8; itraconazole, 0.015-16; fluconazole, 0.012-256; anidulafungin, 0.015-8; and amphotericin B, 0.12-8 . The detailed instructions for the test, as well as interpretation of obtained results, have been presented by us previously (Szweda et al., 2014) .
Gene expression analysis. The yeast isolates were grown on Sabouraud agar plates for 18-20 h at 30 uC. A small amount of biomass from single colonies of each tested strain was suspended in a volume of 4 ml Sabouraud broth and incubated with continuous shaking for about 5 h at 30 uC to achieve an OD 660 of 0.6. The yeast cells were then harvested by centrifugation (4200 g for 5 min) and mRNA was isolated using a Total RNA Mini Plus Concentrator kit (A&A Biotechnology) with the acid phenol method according to the manufacturer's protocol. The isolated RNA was purified with DNase. The reaction mixture was composed of 10 ml sterile RNase-free water, 7 ml isolated RNA solution, 2 ml 10| Reaction Buffer, 1 ml DNase (10 U ml 21 ) (all from A&A Biotechnology) and was incubated at 30 uC for 30 min, and again purified with a Total RNA Mini Plus Concentrator kit. The concentration was determined using a NanoDrop1000 (Thermo Scientific), which showed that double purification resulted in a reduction in efficiency but was necessary to obtain a totally pure mRNA solution that was not contaminated with DNA. Immediately after obtaining the pure mRNA, a reverse transcription reaction with a TranScriba kit (A&A Biotechnology) was carried out. The reaction was done in two steps. In the first, 140 ng isolated RNA was incubated with 1 of oligo(dT) 18 solution (100 mM) and RNasefree water to a volume of 10 ml at 65 uC for 5 min. The following reagents were then added: 4 ml 5| Reaction Buffer, 2 ml dNTP Mix solution (2.5 mM each) and 4 ml TranScriba Reverse Transcriptase (20 U ml 21 ), and the final mixture was incubated at 41 uC for 60 min. The reaction was terminated by heating the sample at 70 uC for 5 min. Quantitative analysis of expression of the ERG11, CDR1, CDR2 and reference URA3 genes was performed by real-time PCR with a LightCycler Nano PCR Real-Time System (Roche). Primers and probes were as designed by Sanguinetti et al. (2005) and were synthesized by Sigma (Table 1) . Real-time PCR was performed with a 20 ml volume containing the following reagents: 10 ml RealTime 2| HS-PCR Master Mix Probe (Taq DNA polymerase 0.1 U ml
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, 2| Reaction Buffer, 10 mM MgCl 2 and 0.5 mM each dNTP (A&A Azole resistance among clinical C. glabrata in Poland Biotechnology), 1 ml each primer solution (10 mM), 0.5 ml probe solution (10 mM), total cDNA sample (1 ml) and distilled water to a final volume of 20 ml. Standard curves for evaluation of real-time PCR efficiency were prepared in triplicate. Twofold serial dilutions of a mixture of the cDNA of all strains tested were used as a template for standard curves in the case of all tested genes. Amplification conditions were as follows: initial denaturation at 95 uC for 5 min, followed by 50 cycles of denaturation at 95 uC for 15 s and 15 s of primer annealing (at 55 uC for URA3, 59 uC for ERG11 and CDR1, and 62 uC for CDR2), with a final elongation step at 72 uC for 15 s. The temperature transition rate was set at 20 uC s
. Genes for gene expression analysis were amplified under the same conditions as for the standard curves, with 7 ng cDNA as template. The experiments were repeated in duplicate for each specimen.
Acquisition of fluorescence signals from up to 32 samples was carried out at the end of every annealing/extension step for 100 ms.
Quantitative analysis of the level of expression of the investigated genes was carried out using the 2 2DDCT method, also known as Livak's method (Livak & Schmittgen, 2001 ). This method allows determination of relative differences in the expression levels of analysed target genes between the investigated strains and reference strain, also called the calibrator. For our research, the Gd6 strain from the Medical University of Gdansk, isolated from throat swab, was selected as the calibrator. The C. glabrata Gd6 strain is recognized as susceptible-dose dependent (S-DD) with a relatively low MIC value for fluconazole of 8 mg ml 21 and is sensitive to other tested azoles: posaconazole, voriconazole and itraconazole. The level of expression of target genes in a particular strain was determined based on comparison of the threshold cycle (C T ) values of amplification of the gene of interest and the reference gene (internal control). As a reference gene for this research, the URA3 gene, one of the housekeeping genes of C. glabrata, which is expressed in cells in a constitutive manner, was used.
Livak's equation value of parameter R51 indicates that the level of target gene expression in the investigated sample (strain) and calibrator are the same. A value w1 indicates a higher level of expression of the tested gene in the cells of the investigated strain in comparison with the cells of the calibrator, whereas a significant increase in the level of the gene expression is considered to have occurred when the value of the parameter R is w2.
According to CLSI (2012) guidelines, all strains tested by real-time PCR (n571) could be divided into two groups: resistant to fluconazole (MIC i64 mg ml
; n515) and S-DD (MIC j32 mg ml 21 ; n556) based on the Sensititre Yeast One test. A real-time PCR was carried out in duplicate for all samples so there were also two R values for each sample. Using the GraphPad Prism 5 program, a statistical analysis was performed and the non-parametric Mann-Whitney U test with a 0.05 level of significance was chosen for comparison of two populations of the R values. A value of Pv0.05 indicated that the compared populations were significantly different.
ERG11 gene sequence analysis. The ERG11 gene was amplified using the set of primers: forward 59-ATGTCCACTGAAAACACTTC-39 and reverse 59-CTAGTACTTTTGTTCTGGATGTC-39, designed on the basis of the sequence encoding the ERG11 gene of C. glabrata CBS 138 (GenBank accession no. XM_445876). PCR was performed in a 50 ml volume containing the following reagents: 25 ml 2| PCR Mix Plus High GC (A&A Biotechnology), 17 ml nuclease-free water, 2.5 ml each primer solution (10 mM) and 3 ml isolated DNA solution. Amplification conditions were as follows: 4 min of initial denaturation at 94 uC, followed by 32 cycles of 60 s of denaturation at 94 uC, 30 s of annealing at 57 uC and 90 s of primer extension at 72 uC, with 10 min of final extension at 72 uC. The PCR products (1602 bp) were detected on 1.5 % agarose gel stained with ethidium bromide. The products of amplification were then purified according to the A&A Biotechnology protocol enclosed with the Clean up AX kit. Sequencing was carried out by Macrogen (The Netherlands). Analysis of sequences was performed using MEGA 6.1 software, and statistical analysis was carried out with the GraphPad Prism 5.0 program.
RESULTS

Species identification and analysis of antifungal resistance
The results of our tests performed by the three methodsyeast growth on a Chromagar Candida Lab-agar plate, an API Candida test and PCR -confirmed that the studied population of 81 clinical isolates consisted exclusively of C. glabrata strains. Analysis of the antifungal resistance of 65 of the isolates has been presented in our previous work (Szweda et al., 2014) , and here we expanded the examined group by adding 16 additional isolates. The strains were categorized as follows: 18 were resistant (MIC i64 mg ml 21 ) and 63 were S-DD to fluconazole (MIC j32 mg ml 21 ). However, for almost all strains tested, except one ). Fifteen of the fluconazoleresistant strains also revealed cross-resistance (classified as non-WT) against the other azoles tested: itraconazole, posaconazole and voriconazole (the MIC breakpoint values for these agents were 4, 2 and 0.5 mg ml 21 , respectively). A further seven isolates were classified as non-WT following analysis of susceptibility to voriconazole. One of these strains was cross-resistant to fluconazole, and thus two isolates were resistant only to fluconazole and six only to voriconazole (Table 2) . Moreover, we examined the susceptibility to three echinocandins, anidulafungin, micafungin and caspofungin, as well as to two other compounds, 5-fluorocytosine and amphotericin B. All strains tested were found to be susceptible to echinocandins and to amphotericin B (the MIC values of all strains for amphotericin B were v1 mg ml 21 ; the susceptibility MIC breakpoint value for classification of strains as non-WT is 2 mg ml 21 ), and nearly all, except for five strains, were classified as WT in terms of susceptibility to 5-fluorocytosine (MIC breakpoint 0.25 mg ml
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).
Three of the five 5-fluorocytosine-resistant strains were able to grow at 5-fluorocytosine concentration as high as 64 mg ml
, which is rarely observed for C. glabrata clinical isolates. All the values of MIC breakpoints presented above are in agreement with the CLSI (2012) guidelines. The number of susceptible, S-DD and resistant strains, or WT or non-WT, to all chemotherapeutics tested are presented in Table 3 .
ERG11 gene sequence analysis
Of the population of 81 isolates of C. glabrata, 41 were selected for sequencing of the ERG11 gene. This group consisted of all strains that exhibited resistance to fluconazole (n518), three strains resistant only to voriconazole and 20 isolates that were not resistant to any of the azoles tested. Analysis of the obtained nucleotide sequences revealed the existence of several cases of silent mutations (not resulting in changes in amino acid sequence of the gene product) within the ERG11 gene. The strains carrying the silent mutations in the ERG11 gene were present in groups, classified as resistant and S-DD (Table S1 , available in the online Supplementary Material). However, none of these mutations resulted in changes in the amino acid sequence of the expressed enzyme (lanosterol 14-a demethylase). This indicated that mechanisms other than substitutions of amino acid residues within the lanosterol 14-a demethylase sequences were responsible for the observed lack of susceptibility to azoles.
Gene expression analysis
Mechanisms of azole resistance among non-albicans candida species are not as well recognized as those for C. albicans, the most common fungal pathogen. Besides mutations within the ERG11 gene sequence, the most important factors causing a low level of activity of azoles against C. albicans are overexpression of genes encoding drug transporters, especially CDR1, and upregulation of genes encoding enzymes involved in biosynthesis of ergosterol, especially lanosterol 14-a demethylase, encoded by the ERG11 gene. As has been presented above, our research on 41 clinical isolates of C. glabrata revealed the presence of only silent mutations within the ERG11 gene sequences. In order to determine the reason for the observed high level of azole resistance among the strains tested, we also analysed the level of expression of the supposed resistance-associated genes CDR1, CDR2 and ERG11 in 71 isolates (including 14 strains classified as resistant to fluconazole and other azoles).
For the CDR1 gene, we found that, in 13 out of 15 (86.6 %) resistant isolates, a significant increase in the level of expression was observed (Fig. 1) . The level of expression increased from 2.07 to 1318.25 (R value) in comparison with the level of expression of this gene in the reference isolate Gd6. In the group of 56 isolates classified as S-DD to fluconazole, 16 (28.6 %) isolates showed a higher level of relative expression, which ranged from 2.27 to 36.13. Statistical analysis revealed the P value of v0.0001. The mean significant difference in the level of the CDR1 gene expression in the group of resistant and non-resistant strains is shown in Fig. 3 .
For the CDR2 gene, overexpression was seen for 13 (22.8 %) of the non-resistant isolates and only five (35.7 %) isolates classified as resistant (Fig. 2) . The values of the R parameter ranged from 0.06 to 18.81 (in general, and from 2.02 to 18.81 when only overexpression was concerned) in non-resistant strains and from 0.29 to 6.36 in resistant strains. It was also observed that the R parameter values were slightly higher in the group of resistant strains. When comparing this parameter with that of the CDR1 gene, the expression levels as well as differences in the expression between both groups of isolates for the CDR2 were much lower. The P value of the Mann-Whitney U test was 0.0681, so the two groups werere not significantly different (Fig. 3 ), which means that the level of expression of CDR2 does not affect the low susceptibility of resistant strains to fluconazole and other tested azoles.
Unexpected results were obtained in the case of analysis of the ERG11 gene expression. Thirty-three (58 %) of the 57 fluconazole non-resistant isolates expressed ERG11 at higher levels than the susceptible control, isolate Gd6, displaying levels of ERG11 transcript that increased from 2.00 to 22.62 (R value) compared with those detected in Gd6.
In contrast, in the group of resistant isolates, such highlevel upregulation of the ERG11 gene was not observed, and the R values ranged from 0.64 to 3.28 compared with the reference. An R value of w2 was observed for the five strains not susceptible to fluconazole (Fig. S1 ). The statistical analysis did not reveal significant differences in the expression level of this gene between resistant and Azole resistance among clinical C. glabrata in Poland S-DD isolates (Fig. 3) . This finding may be interpreted as evidence that moderate overexpression of ERG11 does not contribute to the azole resistance of C. glabrata.
DISCUSSION
C. glabrata is often isolated as a constituent of the natural flora of healthy individuals. For many years, it was not considered an important aetiological agent of serious infections in humans. However, during the last two to three decades, the frequency of mucosal and systemic infections caused by C. glabrata has increased significantly. There is no doubt that this is a consequence of the widespread and increased use of immunosuppressive therapies together with broadspectrum antibiotic treatment (Dzierżanowska-Fangrat et al., 2014; Hajjeh et al., 2004; Rodrigues et al., 2014) .
C. glabrata is a haploid yeast, generally with an intrinsic low susceptibility to azole derivatives, although it can acquire resistance to azoles on exposure to these antifungals more frequently and rapidly than the diploid yeast C. albicans.
Low susceptibility to azoles was also observed in the case of the group of 81 strains investigated in this study. About 20 % were cross-resistant to all tested azoles and, even in the group of strains recognized as non-resistant (S-DD in the case of fluconazole and WT in the case of the other azoles), the MIC values were relatively high (e.g. i8 mg ml 21 for fluconazole, except for one strain). These observations are in agreement with the results of most of investigations concerning azole resistance of clinical isolates of C. glabrata collected in different geographical regions 6  74  75  140  205  226  231  9  19  40  82  99  116  122  127  136  141  143  144  151  154  165  176  182  183  184  198  208  209  215  227  238  240  243  246  247  261  268  273  274  290  315  1w  6w  31w  61w  137w  259w  402s  406s  412s  413s  414s  435s  440s  139  200  211  263  276  286  310  38w  88w  105w  138w  209w  373w  465w  385s -5 properties of the azole-resistant strains, such as morphology and colour of the colonies grown on agar, and growth kinetics in liquid medium, were not different from those of the azole-susceptible strains. High susceptibility to other groups of antifungal agents -echinocandins (Pfaller et al., 2013; Santhanam et al., 2013 ), amphotericin B (Prażyń ska & Gospodarek 2014 Santhanam et al., 2013) and 5-fluorocytosine (Edlind & Katiyar 2010; Pfaller et al., 2002; Santhanam et al., 2013) -is also in agreement with the generally observed trends. However, three of the strains were characterized as extremely highly resistant to 5-fluorocytosine (MIC i64 mg ml
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). The mechanisms for the lack of susceptibility to this agent developed by these isolates will be the subject of further investigations.
Mainly as a result of the widespread use of fluconazole in the treatment and prophylaxis of fungal infections, Candida spp. have evolved a number of mechanisms for resistance to azoles. As far as C. albicans is concerned, several mechanisms have been revealed. A very common mechanism is mutation in the ERG11 gene. Data in the literature suggest that there may be more than 140 different amino acid substitutions within the sequence of the protein encoded by this gene. This high genetic polymorphism suggests that lanosterol 14-a demethylase is highly permissive to structural changes. Most of these substitutions are clustered into three hot-spot regions with aa 105-165, 266-287 and 405-488 (Morio et al., 2010) . In the population of C. glabrata studied here, no mutation in the ERG11 gene resulting in alteration of the lanosterol 14-a demethylase amino acid sequence was found. This finding is in agreement with the results obtained by Sanguinetti et al. (2005) , who did not identify any mutations in the ERG11 gene among 29 clinical isolates of C. glabrata from the University Hospital in Rome, Italy. Actually, the only case of amino acid substitution (G315D) within the sequence of C. glabrata lanosterol 14-a demethylase contributing to azole resistance, which additionally resulted in cross-resistance to amphotericin B, was described by Hull et al. (2012) . Additionally, single-nucleotide substitutions in the ERG11 gene of C. glabrata clinical isolates from Slovakia have been identified, although most were classified as silent mutations, and the only amino acid substitution, E502V, found in some fluconazole-resistant isolates apparently did not contribute to their azole resistance (Berila & Subik, 2010; Berila et al., 2009 ). In our opinion, our obtained results as well as analysis of the literature clearly indicate that mutation of the ERG11 gene should not be considered as an important or common mechanism of resistance of C. glabrata to azole antifungal agents.
It is generally well documented that the most important factor affecting C. glabrata resistance to azole antifungal agents is upregulation of expression of the CDR1 gene (Sanglard et al., 1999 (Sanglard et al., , 2001 Sanguinetti et al., 2005) . This was also confirmed in our investigation. Thirteen out of 15 resistant strains revealed a significant increase in the level of expression of this gene, exceeding 1000-fold in the case of some isolates. This level of CDR1 overexpression was even higher than the highest found so far (260-fold) by Sanguinetti et al. (2005) . However, these authors also found that the azole resistance of the tested strains was importantly affected by upregulation of the CDR2 gene. Eight of the 16 fluconazole-resistant isolates expressed this gene at higher levels than the susceptible control isolate DSY562. Our investigation did not confirm the influence of overexpression of the CDR2 gene in the resistance of strains tested for azole antifungal agents. We also did not find any correlation between azole resistance and the level of expression of the ERG11 gene. Although overexpression of the ERG11 gene was found for some of the isolates, statistical analysis revealed that the mean level of upregulation in the group of resistant strains was not higher than in the group of susceptible ones. In fact, statistically a slightly higher level of transcription of this gene was observed for non-resistant strains classified S-DD, thus confirming the previous observation of Sanguinetti et al. (2005) , who demonstrated that there was no difference in transcription level between the population of resistant and susceptible clinical isolates from Italy. Upregulation of the ERG11 gene was also investigated previously by Marichal et al. (1997) , who noted an eightfold increase in ERG11 mRNA levels in an azole-resistant clinical C. glabrata isolate due to amplification of the ERG11 gene, which in turn resulted from chromosomal duplication. To date, there have been no more cases that could confirm the dependence of resistance of C. glabrata to azoles and upregulation of the ERG11 gene.
In conclusion, the results obtained in the present study emphasize the role of upregulation of the CDR1 gene encoding the ABC efflux transporter as the major mechanism of azole resistance in C. glabrata. From this point of view, C. glabrata is similar to C. albicans. In contrast, it is totally different as far as the CDR2 and especially the ERG11 genes are concerned. Neither point mutations nor upregulation at a transcriptional level of ERG11 were observed. We also did not observe statistically important differences in the level of CDR2 gene expression between resistant and susceptible isolates. This may suggest that drug resistance mechanisms can be very different, even within a genus of yeasts, and more studies are needed. In most publications concerning azole resistance among Candida spp., the authors mention ERG11 gene mutations and overexpression of this gene, as well as upregulation of genes encoding the efflux pumps (CDR1 and CDR2) as major causes of resistance. In our opinion, there is still not enough evidence, not only in this investigation but also in the literature, to confirm that point mutations of the ERG11 gene as well as upregulation of the ERG11 and CDR2 genes can be considered important or common mechanisms of resistance among C. glabrata.
The molecular basis of azole resistance in two out of 15 of our fluconazole-resistant isolates not overexpressing CDR1 remains unknown. This resistance might have resulted from overexpression of SNQ2 encoding another ABCtype multidrug-transporter protein, overexpression of TPO3 encoding the MFS-type drug efflux pump (Costa et al., 2014) or mutations in PDR1 encoding the transcriptional activator protein, responsible for controlling the level of expression of genes encoding drug efflux transporters including CDR1 (Paul et al., 2014) or any other mechanism. It should be noted that the slight overexpression of SNQ2 found by Sanguinetti et al. (2005) in their C. glabrata azole-resistant clinical isolates not overexpressing CDR1 or CDR2 was not directly correlated with the high level of azole resistance, and no evidence for an important contribution of PDR1 or TPO3 upregulation in the azole resistance of C. glabrata clinical isolates has been reported so far. A detailed explanation of the mechanisms governing the overexpression of CDR1, including sequencing of PDR1, in the cells of the investigated resistant strains will be the subject of our future research.
